No evidence for neuronal damage or astrocytic activation in cerebrospinal fluid of Neuro-COVID-19 patients with long-term persistent headache
-
Published:2023-09-28
Issue:1
Volume:5
Page:
-
ISSN:2524-3489
-
Container-title:Neurological Research and Practice
-
language:en
-
Short-container-title:Neurol. Res. Pract.
Author:
de Boni Laura,Odainic Alexandru,Gancarczyk Natalie,Kaluza Luisa,Strassburg Christian P.,Kersting Xenia A. K.,Wüllner Ullrich,Schmidt Susanne V.,Petzold Gabor C.
Abstract
AbstractHeadache is one of the most common neurological manifestations of COVID-19, but it is unclear whether chronic headache as a symptom of Post-COVID-19 is associated with ongoing CNS damage. We compared cerebrospinal fluid (CSF) levels of markers of CNS damage and inflammation in Post-COVID-19 patients with persistent headache to hospitalized acute COVID-19 patients with neurological symptoms and to non-COVID-19 disease-controls. CSF levels of neurofilament light chain, Ubiquitin carboxyl-terminal hydrolase L1 and Tau were similar in patients with persistent headache in post-COVID-19 compared to acute COVID-19 patients and all control groups. Levels of glial fibrillary astrocytic protein were lower in patients with persistent headache in post-COVID-19 compared to some control groups of patients with neurological disease. Therefore, our pilot study of CSF markers indicates that persistent post-COVID-19 headache is not a sign of underlying neuronal damage or glial activation.
Funder
HORIZON EUROPE Excellent Science
Publisher
Springer Science and Business Media LLC
Subject
Neurology (clinical),Neurology
Reference10 articles.
1. Guerrero, J. I., Barragán, L. A., Martínez, J. D., Montoya, J. P., Peña, A., Sobrino, F. E., Tovar-Spinoza, Z., & Ghotme, K. A. (2021). Central and peripheral nervous system involvement by COVID-19: A systematic review of the pathophysiology, clinical manifestations, neuropathology, neuroimaging, electrophysiology, and cerebrospinal fluid findings. BMC Infectious Diseases, 21(1), 515. https://doi.org/10.1186/s12879-021-06185-6. 2. de Boni, L., Odainic, A., Gancarczyk, N., Kaluza, L., Strassburg, C. P., Kersting, X. A. K., Johnson, J. M., Wüllner, U., Schmidt, S. V., Nattermann, J., & Petzold, G. C. (2022). No serological evidence for neuronal damage or reactive gliosis in neuro-COVID-19 patients with long-term persistent headache. Neurological Research and Practice, 4(1), 53. https://doi.org/10.1186/s42466-022-00217-5. 3. Chaumont, H., Kaczorowski, F., San-Galli, A., Michel, P. P., Tressières, B., Roze, E., Quadrio, I., & Lannuzel, A. (2022). Cerebrospinal fluid biomarkers in SARS-CoV-2 patients with acute neurological syndromes. Revue Neurologique. https://doi.org/10.1016/j.neurol.2022.11.002. Advance online publication. 4. Edén, A., [Arvid], Grahn, A., Bremell, D., Aghvanyan, A., Bathala, P., Fuchs, D., Gostner, J., Hagberg, L., Kanberg, N., Kanjananimmanont, S., Lindh, M., Misaghian, S., Nilsson, S., Schöll, M., Sigal, G., Stentoft, E., Studahl, M., Yilmaz, A., Wang, M., & Gisslén, M. (2022). Viral Antigen and inflammatory biomarkers in cerebrospinal fluid in patients with COVID-19 infection and neurologic symptoms compared with control participants without infection or neurologic symptoms. JAMA Network Open, 5(5), e2213253. https://doi.org/10.1001/jamanetworkopen.2022.13253. 5. Virhammar, J., Nääs, A., Fällmar, D., Cunningham, J. L., Klang, A., Ashton, N. J., Jackmann, S., Westman, G., Frithiof, R., Blennow, K., Zetterberg, H., Kumlien, E., & Rostami, E. (2021). Biomarkers for central nervous system injury in cerebrospinal fluid are elevated in COVID-19 and associated with neurological symptoms and disease severity. European Journal of Neurology, 28(10), 3324–3331. https://doi.org/10.1111/ene.14703.
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
|
|